Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2022

Open Access 01-12-2022 | Care | Study protocol

Securing jugular central venous access devices with dressings fixed to a liquid adhesive in an intensive care unit population: a randomised controlled trial

Authors: India Pearse, Amanda Corley, Emily N. Larsen, Claire M. Rickard, Robert S. Ware, Jill Campbell, Fiona Coyer, Evan Alexandrou, Catherine O’Brien, Nicole Marsh

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

Central venous access devices (CVADs) can have high rates of failure due to dressing-related complications. CVADs placed in the internal jugular vein are at particular risk of dressing failure-related complications, including catheter-associated bloodstream infection and medical adhesive-related skin injury. Application of Mastisol liquid adhesive (MLA) may reduce CVAD dressing failure and associated complications, by reducing the frequency of dressing changes. The aim of this study is to investigate whether, in an intensive care unit (ICU) population, standard dressing care with or without the addition of MLA, improves internal jugular CVAD dressing adherence.

Methods

This two-arm, parallel group randomised controlled trial will be conducted in three Australian ICUs. A total of 160 patients (80 per group) will be enrolled in accordance with study inclusion and exclusion criteria. Patients will be randomised to receive either (1) ‘standard’ (in accordance with local hospital policy) CVAD dressings (control) or (2) ‘standard’ dressings in addition to MLA (intervention). Patients will be followed from the time of CVAD insertion to 48 h after CVAD removal. The primary outcome is ‘dressing failure’ defined as requirement for initial CVAD dressing to be replaced prior to seven days (routine replacement).

Discussion

This study will be the first randomised controlled trial to evaluate the clinical effectiveness of MLA in the adult intensive care unit population and will also provide crucial data for patient-important outcomes such as infection and skin injury.

Trial registration

Australian New Zealand Clinical Trials Registry ACTRN12621001012​864. Registered on 2 August 2021
Literature
1.
Ullman AJ, Marsh N, Mihala G, Cooke M, Rickard CM. Complications of central venous access devices: a systematic review. Pediatrics. 2015;136(5):e1331–e44.CrossRef
2.
Rickard C, Edwards M, Spooner A, Mihala G, Marsh N, Best J, et al. A 4-arm randomized controlled pilot trial of innovative solutions for jugular central venous access device securement in 221 cardiac surgical patients. J Crit Care. 2016;36:35–42.CrossRef
3.
Tuffaha HW, Marsh N, Byrnes J, Gavin N, Webster J, Cooke M, et al. Cost of vascular access devices in public hospitals in Queensland. Aust Health Rev. 2019;43(5):511–5.CrossRef
4.
Corley A, Marsh N, Ullman AJ, Rickard CM. Tissue adhesive for vascular access devices: who, what, where and when? Br J Nurs. 2017;26(19):S4–S17.CrossRef
5.
Napalkov P, Felici DM, Chu LK, Jacobs JR, Begelman SM. Incidence of catheter-related complications in patients with central venous or hemodialysis catheters: a health care claims database analysis. BMC Cardiovasc Disord. 2013;13(1):86.CrossRef
6.
Rosenthal VD, Guzman S, Migone O, Crnich CJ. The attributable cost, length of hospital stay, and mortality of central line-associated bloodstream infection in intensive care departments in Argentina: a prospective, matched analysis. Am J Infect Control. 2003;31(8):475–80.CrossRef
7.
Periard D, Monney P, Waeber G, Zurkinden C, Mazzolai L, Hayoz D, et al. Randomized controlled trial of peripherally inserted central catheters vs. peripheral catheters for middle duration in-hospital intravenous therapy. J Thromb Haemost. 2008;6(8):1281–8.CrossRef
8.
O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control. 2011;39(4 Suppl 1):S1–34.CrossRef
9.
Infusion Nurses Society. Infusion therapy standard of practice (8th ed.). J Infus Nurs. 2021;44(1S):S1–224.CrossRef
10.
Ullman AJ, Cooke ML, Mitchell M, Lin F, New K, Long DA, et al. Dressings and securement devices for central venous catheters (CVC). Cochrane Database of Syst Rev. 2015;9:CD010367.
11.
Naimer SA, Temira F. Evaluation of techniques for intravenous catheter and tubing fixation. Mil Med. 2004;169(1):79–81.CrossRef
12.
Ryder M, Duley C. Evaluation of compatibility of a gum mastic liquid adhesive and liquid adhesive remover with an alcoholic chlorhexidine gluconate skin preparation. J Infus Nurs. 2017;40(4):245–52.CrossRef
13.
Broadhurst D, Moureau N, Ullman AJ. Management of central venous access device-associated skin impairment: an evidence-based algorithm. J Wound Ostomy Continence Nurs. 2017;44(3):211–20.CrossRef
14.
Ullman AJ, Mihala G, O’Leary K, Marsh N, Woods C, Bugden S, et al. Skin complications associated with vascular access devices: a secondary analysis of 13 studies involving 10,859 devices. Int J Nurs Stud. 2019;91:6–13.CrossRef
15.
Timsit J-F, Bouadma L, Ruckly S, Schwebel C, Garrouste-Orgeas M, Bronchard R, et al. Dressing disruption is a major risk factor for catheter-related infections. Crit Care Med. 2012;40(6):1707–14.CrossRef
16.
McCord J, Niehaus S. Improving adhesion of internal jugular dressings in the intensive care unit. JAVA. 2016;4(21):251–2.CrossRef
17.
The Prince Charles Hospital. Central venous line/PICC line/vascath equipment required for insertion. 2021.
18.
South Western Sydney Local Health District. Policy directive: Central venous access device (CVAD) post insertion management (SWSLHD_PD2018_011). 2018.
19.
20.
21.
22.
Fumarola S, Allaway R, Callaghan R, Collier M, Downie F, Geraghty J, et al. Overlooked and underestimated: medical adhesive-related skin injuries. J Wound Care. 2020;29(Sup3c):S1–24.CrossRef
23.
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.CrossRef
24.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.CrossRef
25.
Metadata
Title
Securing jugular central venous access devices with dressings fixed to a liquid adhesive in an intensive care unit population: a randomised controlled trial
Authors
India Pearse
Amanda Corley
Emily N. Larsen
Claire M. Rickard
Robert S. Ware
Jill Campbell
Fiona Coyer
Evan Alexandrou
Catherine O’Brien
Nicole Marsh
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Care
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06322-9

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue

Study protocol

A multicenter non-inferior randomized controlled study comparing the efficacy of laparoscopic versus abdominal radical hysterectomy for cervical cancer (stages IB1, IB2, and IIA1): study protocol of the LAUNCH 2 trial

Research

Overestimation of benefit when clinical trials stop early: a simulation study

Study protocol

Swedish trial on embolization of middle meningeal artery versus surgical evacuation in chronic subdural hematoma (SWEMMA)—a national 12-month multi-center randomized controlled superiority trial with parallel group assignment, open treatment allocation and blinded clinical outcome assessment

Study protocol

Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study

Study protocol

Intraoperative endoluminal pyloromyotomy for reduction of delayed gastric emptying after pylorus preserving partial pancreaticoduodenectomy (PORRIDGE trial): study protocol for a randomised controlled trial

Study protocol

Kangyi Qiangshen Gong exercise prescription for pulmonary function and quality of life in patients recovered from COVID-19: a study protocol for a randomized controlled trial